Takeda, Sosei form gastrointestinal disease R&D pact

Takeda and Sosei Heptares have entered into a multi-target R&D agreement. Sosei is set to receive $26 million (€23 million) in upfront and near-term payments, plus up to $1.2 billon in milestones, to apply its GPCR expertise to targets of interest to Takeda.